Vir Biotechnology, Inc. (NASDAQ:VIR) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) have received an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $21.86.

A number of brokerages have recently commented on VIR. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Friday, October 2nd. Raymond James Financial restated a “strong-buy” rating on shares of Vir Biotechnology in a report on Monday, September 28th. HC Wainwright boosted their target price on Vir Biotechnology from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Wednesday, October 7th. Morgan Stanley set a $25.00 target price on Vir Biotechnology in a research report on Thursday, August 6th. Finally, Zacks Research lowered Vir Biotechnology from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 6th.

Vir Biotechnology Trading Down 3.8%

NASDAQ:VIR opened at $11.30 on Friday. The company has a 50-day moving average of $10.94 and a 200-day moving average of $9.49. The firm has a market cap of $1.91 billion, a price-to-earnings ratio of -6.08 and a beta of 1.59. Vir Biotechnology has a twelve month low of $4.82 and a twelve month high of $12.19.

Vir Biotechnology (NASDAQ:VIR) last released its earnings results on Wednesday, August 5th. The company reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.14. The business had revenue of $238.95 million during the quarter, compared to the consensus estimate of $135.88 million. The firm’s revenue for the quarter was up 19582.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.80) earnings per share. On average, research analysts forecast that Vir Biotechnology will post -1.84 earnings per share for the current year.

Institutional Trading of Vir Biotechnology

A number of hedge funds have recently bought and sold shares of the company. Fiduciary Financial Advisors purchased a new stake in shares of Vir Biotechnology in the 2nd quarter valued at approximately $29,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in Vir Biotechnology during the 3rd quarter worth approximately $97,000. Caxton Associates LLP purchased a new position in Vir Biotechnology during the 1st quarter worth approximately $112,000. Amundi raised its stake in Vir Biotechnology by 52.8% during the 1st quarter. Amundi now owns 15,315 shares of the company’s stock valued at $137,000 after purchasing an additional 5,294 shares during the period. Finally, Royal Bank of Canada raised its stake in Vir Biotechnology by 223.1% during the 1st quarter. Royal Bank of Canada now owns 15,355 shares of the company’s stock valued at $138,000 after purchasing an additional 10,603 shares during the period. 65.32% of the stock is owned by hedge funds and other institutional investors.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical-stage immunology company focused on developing medicines to prevent and treat serious infectious diseases and other immune-related conditions. The company uses antibody engineering, immunologic approaches and other technologies to identify and advance therapies designed to harness or modify the immune system.

Vir’s research and development programs have included treatments and vaccines for hepatitis B, human immunodeficiency virus (HIV), influenza and other infectious diseases.